339 related articles for article (PubMed ID: 36938325)
41. In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1.
Pochtovyi AA; Kustova DD; Siniavin AE; Dolzhikova IV; Shidlovskaya EV; Shpakova OG; Vasilchenko LA; Glavatskaya AA; Kuznetsova NA; Iliukhina AA; Shelkov AY; Grinkevich OM; Komarov AG; Logunov DY; Gushchin VA; Gintsburg AL
Vaccines (Basel); 2023 Sep; 11(10):. PubMed ID: 37896937
[TBL] [Abstract][Full Text] [Related]
42. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D
J Gen Virol; 2023 May; 104(5):. PubMed ID: 37167085
[TBL] [Abstract][Full Text] [Related]
43. A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB.
Ding Y; Fan F; Xu X; Zhao G; Zhang X; Zhao H; Wang L; Wang B; Gao XM
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112691
[TBL] [Abstract][Full Text] [Related]
44. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
[TBL] [Abstract][Full Text] [Related]
45. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
[TBL] [Abstract][Full Text] [Related]
46. Continued evasion of neutralizing antibody response by Omicron XBB.1.16.
Faraone JN; Qu P; Zheng YM; Carlin C; Jones D; Panchal AR; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Cell Rep; 2023 Oct; 42(10):113193. PubMed ID: 37777967
[TBL] [Abstract][Full Text] [Related]
47. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2.
Thimmiraju SR; Adhikari R; Villar MJ; Lee J; Liu Z; Kundu R; Chen YL; Sharma S; Ghei K; Keegan B; Versteeg L; Gillespie PM; Ciciriello A; Islam NY; Poveda C; Uzcategui N; Chen WH; Kimata JT; Zhan B; Strych U; Bottazzi ME; Hotez PJ; Pollet J
Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896960
[TBL] [Abstract][Full Text] [Related]
48. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Bolland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
Nat Commun; 2024 Mar; 15(1):2254. PubMed ID: 38480689
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY
Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978
[TBL] [Abstract][Full Text] [Related]
50. Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1.
Wang J; Shi B; Chen H; Yu M; Wang P; Qian Z; Hu K; Wang J
Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675799
[TBL] [Abstract][Full Text] [Related]
51. Balancing Functional Tradeoffs between Protein Stability and ACE2 Binding in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB Lineages: Dynamics-Based Network Models Reveal Epistatic Effects Modulating Compensatory Dynamic and Energetic Changes.
Verkhivker G; Alshahrani M; Gupta G
Viruses; 2023 May; 15(5):. PubMed ID: 37243229
[TBL] [Abstract][Full Text] [Related]
52. Computational Investigation of Selected Spike Protein Mutations in SARS-CoV-2: Delta, Omicron, and Some Circulating Subvariants.
Roy U
Pathogens; 2023 Dec; 13(1):. PubMed ID: 38276156
[TBL] [Abstract][Full Text] [Related]
53. EFFECT OF RBD MUTATIONS IN SPIKE GLYCOPROTEIN OF SARS-COV-2 ON NEUTRALIZING IGG AFFINITY.
Hayashi T; Yaegashi N; Konishi I
Georgian Med News; 2023; (340-341):37-46. PubMed ID: 37805871
[TBL] [Abstract][Full Text] [Related]
54. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Boland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; ; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
bioRxiv; 2024 Feb; ():. PubMed ID: 38045308
[TBL] [Abstract][Full Text] [Related]
55. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
Akkız H
Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
Trombetta CM; Marchi S; Leonardi M; Coppola C; Benincasa L; Marotta MG; Buonvino N; Maes P; Stufano A; Pontrelli D; Vasinioti VI; Manenti A; Camero M; Montomoli E; Decaro N; Lovreglio P
Acta Trop; 2023 Dec; 248():107042. PubMed ID: 37863379
[TBL] [Abstract][Full Text] [Related]
57. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.
Qu P; Evans JP; Faraone J; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
bioRxiv; 2022 Oct; ():. PubMed ID: 36299423
[TBL] [Abstract][Full Text] [Related]
58. Genomic Surveillance Reveals the Rapid Expansion of the XBB Lineage among Circulating SARS-CoV-2 Omicron Lineages in Southeastern Wisconsin, USA.
Ramaiah A; Khubbar M; Akinyemi K; Bauer A; Carranza F; Weiner J; Bhattacharyya S; Payne D; Balakrishnan N
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766346
[TBL] [Abstract][Full Text] [Related]
59. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters.
Halfmann PJ; Iwatsuki-Horimoto K; Kuroda M; Hirata Y; Yamayoshi S; Iida S; Uraki R; Ito M; Ueki H; Furusawa Y; Sakai-Tagawa Y; Kiso M; Armbrust T; Spyra S; Maeda K; Wang Z; Imai M; Suzuki T; Kawaoka Y
Commun Biol; 2024 Mar; 7(1):331. PubMed ID: 38491227
[TBL] [Abstract][Full Text] [Related]
60. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
